In Vivo Quantitative Imaging of Gliomas

Dear Colleagues,

In vivo imaging has great value for brain studies because it can be done non-invasively, can sample the entire brain including both tumor and healthy brain tissue, and can be easily repeated. These features are difficult to achieve in brain when using other means, such as biopsies. Hence, there is high motivation for advancing glioma imaging, which is growing at a fast pace fueled by advances in aspects of imaging platforms including hardware, software, and imaging agents.

Quantitative imaging is being translated into the clinical workflow, where it enables precision oncology in glioma patients, and is being recognized and requested by neurooncologists and neurosurgeons toward improving outcomes for these patients.

For this Special Issue, we would like to invite papers that cover the entire breath of in vivo imaging for glioma—from technical development to clinical applications and from animal to human studies.

We are interested in technical development research articles presenting new imaging hardware platforms, imaging software methods for acquisition/reconstruction/analysis/reporting enhanced by deep learning, and molecular imaging agents. Methods that combine and leverage advances in multiple fields such as imaging genomics, (radiogenomics), artificial intelligence, therapy, and diagnostics have great potential to have a significant impact in clinical arena.

We seek to promote clinical applications related to diagnosis, treatment planning, and treatment response assessment of novel targeted treatments in glioma patients performed first in either human or large multi-center studies. In addition, we value research articles that bring new understanding of the mechanisms of tumor formation, response, and relapse either in animal models or human studies.

In addition to non-invasive imaging methods based on CT, MRI, PET, SPECT, and US, we welcome intraoperative imaging methods such as fluorescence (5-ALA) and Raman spectroscopy applied in glioma surgery.

We look forward to receiving submissions of cutting-edge and breakthrough research that will improve the outcomes and clinical needs of glioma patients.

Dr. Ovidiu Andronesi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.